ELAB Narrows Losses, Boosts Cash Post-Skincare Divestiture

Ticker: ELAB · Form: 10-Q · Filed: Aug 13, 2025 · CIK: 1840563

Sentiment: mixed

Topics: Biotechnology, Medical Aesthetics, Reverse Stock Split, Net Loss, Cash Flow, Discontinued Operations, SEC Filing

Related Tickers: ELAB

TL;DR

**ELAB is cleaning house and raising cash, but the operational burn is still a concern; watch for a clear path to profitability post-divestiture.**

AI Summary

PMGC Holdings Inc. (ELAB) reported a net loss of $562,355 for the three months ended June 30, 2025, a significant improvement from the $1,412,491 net loss in the prior-year period. For the six months ended June 30, 2025, the net loss was $2,170,810, down from $2,809,741 in the same period of 2024. Total operating expenses increased to $1,013,518 for the three months ended June 30, 2025, from $556,242 in the prior year, driven by higher consulting fees ($198,345 vs. $179,843) and professional fees ($284,175 vs. $48,706). The company's cash position improved substantially, reaching $5,682,628 as of June 30, 2025, up from $3,984,453 at December 31, 2024, primarily due to $4,410,768 in financing activities, including $1,519,437 from an ATM agreement. A key business change was the sale of its skincare business, which closed on January 16, 2025, and is now presented as discontinued operations. The company also completed two reverse stock splits, a 1-for-200 on November 27, 2024, and a 1-for-7 on March 10, 2025, retrospectively adjusting share counts.

Why It Matters

For investors, ELAB's reduced net loss and strengthened cash position, driven by financing activities and the divestiture of its skincare business, suggest a potential pivot and improved financial stability. The significant increase in professional and consulting fees, however, warrants scrutiny as it impacts profitability. The competitive landscape in medical aesthetics and biotechnology is intense, and ELAB's ability to leverage its intellectual property through Northstrive Biosciences Inc. will be crucial for future growth and market positioning. Employees might see a more focused company post-divestiture, while customers of the divested skincare business will now interact with a new entity. The broader market will watch if ELAB can translate its improved liquidity into sustainable operational success.

Risk Assessment

Risk Level: medium — The company reported a net loss of $2,170,810 for the six months ended June 30, 2025, indicating continued unprofitability. While cash increased to $5,682,628, this was largely due to $4,410,768 from financing activities, including an ATM program, rather than operational cash generation, suggesting ongoing reliance on external funding.

Analyst Insight

Investors should monitor ELAB's future filings closely for signs of improved operational efficiency and a clear strategy for generating revenue from its remaining biotechnology and intellectual property assets. The recent capital raises provide a buffer, but sustained losses necessitate a defined path to profitability before considering a long-term position.

Financial Highlights

total Assets
$9,375,476
total Debt
$326,301
net Income
-$562,355
cash Position
$5,682,628

Key Numbers

Key Players & Entities

FAQ

What were PMGC Holdings Inc.'s key financial results for the quarter ended June 30, 2025?

PMGC Holdings Inc. reported a net loss of $562,355 for the three months ended June 30, 2025, a decrease from the $1,412,491 net loss in the same period of 2024. Cash increased to $5,682,628 as of June 30, 2025, up from $3,984,453 at December 31, 2024.

How did PMGC Holdings Inc.'s operating expenses change in the second quarter of 2025?

Total operating expenses for PMGC Holdings Inc. increased to $1,013,518 for the three months ended June 30, 2025, compared to $556,242 for the same period in 2024. This rise was primarily due to higher professional fees of $284,175 and consulting fees of $198,345.

What strategic business changes did PMGC Holdings Inc. undertake recently?

PMGC Holdings Inc. completed the sale of its skincare business on January 16, 2025, which is now reported as discontinued operations. The company also underwent a redomiciling from Delaware to Nevada and completed two reverse stock splits, a 1-for-200 on November 27, 2024, and a 1-for-7 on March 10, 2025.

What is the impact of the reverse stock splits on ELAB's shares?

PMGC Holdings Inc. completed a 1-for-200 reverse stock split on November 27, 2024, and a subsequent 1-for-7 reverse stock split on March 10, 2025. On a combined basis, this reflects a retrospective reverse stock split of 1-for-1,400, significantly reducing the number of outstanding common shares to 1,484,827 as of August 12, 2025.

What are the primary risks highlighted in PMGC Holdings Inc.'s 10-Q filing?

The filing highlights risks such as general economic conditions, competitive product pricing, costs associated with R&D, the impact of public health threats like COVID-19, political unrest, data security breaches, and the ability to raise sufficient funds to execute its business plan. The company's continued net loss of $2,170,810 for the six months ended June 30, 2025, also indicates ongoing financial risk.

How did PMGC Holdings Inc. fund its operations during the first half of 2025?

PMGC Holdings Inc. primarily funded its operations through financing activities, which provided $4,410,768 in cash during the six months ended June 30, 2025. This included $1,938,772 from the exercise of Series A warrants and $1,519,437 from the issuance of common shares under an ATM agreement.

What was the change in PMGC Holdings Inc.'s total assets and liabilities?

As of June 30, 2025, PMGC Holdings Inc.'s total assets were $9,375,476, an increase from $8,993,165 at December 31, 2024. Total liabilities significantly decreased to $326,301 from $2,333,601 over the same period, largely due to the removal of liabilities held for sale and consideration payable.

What is the significance of the 'discontinued operations' section in ELAB's financial statements?

The 'discontinued operations' section reflects the sale of PMGC Holdings Inc.'s skincare business, which closed on January 16, 2025. This means the financial results of the skincare business are now reported separately, allowing investors to better assess the performance of the company's continuing operations, which reported a net loss from continuing operations of $2,160,301 for the six months ended June 30, 2025.

Who are the key subsidiaries of PMGC Holdings Inc.?

PMGC Holdings Inc. has several 100% owned subsidiaries: PMGC Research Inc. (formerly Elevai Research Inc), PMGC Impasse Corp (formerly Elevai Skincare Inc.), Northstrive Biosciences Inc. (formerly Elevai Biosciences, Inc), and PMGC Capital LLC. Northstrive Biosciences Inc. is specifically purposed to hold and develop the Company's intellectual property.

What was the accumulated deficit for PMGC Holdings Inc. as of June 30, 2025?

As of June 30, 2025, PMGC Holdings Inc.'s accumulated deficit was $15,440,437. This represents an increase from an accumulated deficit of $13,269,627 at December 31, 2024, reflecting the ongoing net losses incurred by the company.

Risk Factors

Industry Context

PMGC Holdings Inc. operates in a dynamic sector, likely related to healthcare or biotechnology given its former name 'Elevai Labs Inc.' and the sale of a skincare business. The industry is characterized by significant research and development costs, regulatory hurdles, and intense competition. Companies in this space often rely on external financing to fund growth and innovation.

Regulatory Implications

As a publicly traded company, PMGC is subject to SEC regulations and reporting requirements. The reverse stock splits and the classification of discontinued operations are standard disclosures but require careful adherence to accounting standards. Any future product development or market entry would necessitate compliance with relevant industry-specific regulations.

What Investors Should Do

  1. Monitor operating expense trends
  2. Assess path to profitability
  3. Analyze cash flow drivers
  4. Understand the impact of discontinued operations

Key Dates

Glossary

Discontinued operations
A component of a business that the reporting entity has disposed of or classified as held for sale, and that represents a separate major line of business or geographical area of operations. (The sale of PMGC's skincare business is reported under this classification, affecting the presentation of financial results.)
Reverse stock split
A corporate action in which a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (PMGC completed two reverse stock splits, significantly altering its share structure and impacting metrics like earnings per share.)
ATM agreement
At-the-market agreement, a type of equity offering where a company sells shares to the public over a period of time at prevailing market prices. (Proceeds from an ATM agreement contributed significantly to PMGC's financing activities and improved its cash position.)
Accumulated deficit
The cumulative net losses of a company that have not been offset by net income or other adjustments to equity. (PMGC has a substantial accumulated deficit of $(15,440,437) as of June 30, 2025, reflecting its history of net losses.)
Intangibles, net
Represents the net book value of intangible assets, such as patents, trademarks, or goodwill, after deducting accumulated amortization. (Intangible assets decreased from $2,801,993 at December 31, 2024, to $2,072,632 at June 30, 2025, partly due to a gain on termination.)

Year-Over-Year Comparison

Compared to the prior year, PMGC Holdings Inc. has significantly reduced its net loss for both the three months ended June 30, 2025 ($562,355 vs. $1,412,491) and the six months ended June 30, 2025 ($2,170,810 vs. $2,809,741). While revenue figures are not explicitly detailed for comparison, operating expenses have notably increased to $1,013,518 in Q2 2025 from $556,242 in Q2 2024, driven by higher consulting and professional fees. The company's cash position has strengthened considerably, up to $5,682,628 from $3,984,453 at the end of 2024, primarily due to robust financing activities.

Filing Stats: 4,511 words · 18 min read · ~15 pages · Grade level 17.5 · Accepted 2025-08-12 21:48:00

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q (this "Quarterly Report") of PMGC Holdings Inc. ("we," "us," "our," "PMGC" and the "Company") contains statements that constitute "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical facts may be deemed to be forward-looking statements. These statements appear in several different places in this Quarterly Report and, in some cases, can be identified by words such as "anticipates," "estimates," "projects," "expects," "contemplates," "intends," "believes," "plans," "may," "will" or their negatives or other comparable words, although not all forward-looking statements contain these identifying words. Forward-looking and projections; our business prospects and opportunities; our business strategy and future operations; the projection of timing and delivery of products in the future; projected costs; expected production capacity; expectations regarding demand and acceptance of our products; estimated costs of research and development to develop new pipeline products; trends in the market in which we operate; the plans and objectives of management; our liquidity and capital requirements, including cash flows and uses of cash; trends relating to our industry; and plans relating to our current products. We have based these forward-looking statements on our current expectations about future events on information that is available as of the date of this Quarterly Report, and any forward-looking statements made by us speak only as of the date on which they are made. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. O

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Condensed Consolidated

Financial Statements of

Financial Statements of PMGC Holdings Inc. (formerly Elevai Labs Inc.) For the quarterly periods ended June 30, 2025, and 2024 (Unaudited - Expressed in United States Dollars) PMGC Holdings Inc. (formerly Elevai Labs Inc.) Condensed Consolidated Balance Sheets (Unaudited - Expressed in United As of: June 30, 2025 December 31, 2024 ASSETS Current Assets Cash $ 5,682,628 $ 3,984,453 Receivables, net - 5,276 Prepaids and deposits 791,055 868,464 Short-term loan receivable 128,111 - Other receivables 76,212 - Investment in securities- current 624,838 - Assets held for sale - 1,192,808 Total Current Assets 7,302,844 6,051,001 Investment in securities-noncurrent - 139,084 Equipment, net - 1,087 Intangibles, net 2,072,632 2,801,993 TOTAL ASSETS $ 9,375,476 $ 8,993,165 LIABILITIES Current Liabilities Accounts payable and accrued liabilities $ 271,567 $ 481,001 Due to related parties 54,734 419,217 Current portion of consideration payable - 350,000 Liabilities held for sale - 548,916 Total Current Liabilities 326,301 1,799,134 Consideration payable - 534,467 TOTAL LIABILIITES $ 326,301 $ 2,333,601 Commitments and Contingencies EQUITY Preferred stock $ 0.0001 par value; 500,000,000 stock authorized: Series B preferred stock, 6,372,874 and Nil shares issued and outstanding as of June 30, 2025, and December 31, 2024, respectively 637 - Common stock, $ 0.0001 par value, 285,714,286 shares authorized; 1,477,575 and 438,987 shares issued and outstanding as of June 30, 2025, and December 31, 2024, respectively (1) 148 44 Additional paid-in capital 24,490,049 19,929,484 Accumulated other comprehensive income ( 1,222 ) ( 337 ) Accumulated deficit ( 15,440,437 ) ( 13,269,627 ) TOTAL EQUITY 9,049,175 6,659,564 TOTAL LIABILITIES AND EQUITY $ 9,375,476 $ 8,993,165 (1) Reflects retrospectively the 1-for-200 reverse stock split that became effect

financial statements include the accounts of PMGC and its 100 % owned subsidiaries,

financial statements include the accounts of PMGC and its 100 % owned subsidiaries,

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing